A recent publication in Clinical Pharmacology and Therapeutics (CPT) by van der Wouden and colleagues on the preemptive pharmacogenomic PGx Passport, intended to optimize drug prescribing, caught my attention. I believe that the overall narrative of the paper is disproportional to the supporting evidence. The Editors of CPT did not find that my comment and reflections on this paper could be prioritized. I hope that BCPT will endorse a discussion of how we, as a research community, frame and disseminate our findings.